Venture capital work continues to strengthen back-end services, Pudong's investment in two biopharmaceutical companies has brought good news
On June 27, Pudong Venture Capital launched the "Chuang" Enterprise Hui post-investment service characteristic party-building brand, which will focus on improving the efficiency of project post-investment management. By linking policies, finance, industrial resources and application scenarios, it will integrate a diversified and integrated "enterprise assistance service package" covering ten major resources including financial assistance to enterprises, industrial and financial docking, policy interpretation, and industry research, to provide value-added empowerment services to invested enterprises.
The reporter learned that in January this year, Pudong Venture Capital was listed and operated, focusing on the "guidance and gap filling" function of state-owned venture capital, focusing on the transformation of scientific and technological achievements, and playing the counter-cyclical investment role of state-owned venture capital when the venture capital market enters a low period.
This year, Pudong Venture Capital has held dozens of series of activities such as the AI New Productivity Development Forum through project roadshows, industry sharing, and corporate promotions. During this period, it has helped more than 20 companies such as Kezhou Pharmaceuticals, Mekamind, Lianren Health, Pudirui, and Yunmai Xinlian to help companies expand their industry "circle of friends" and deeply connect with the capital market.
Among them, Pudong Venture Capital has been following up on Kezhou Pharmaceuticals for two or three years, and has maintained close contact with the company during this period, helping the company accelerate the research and development of core products from aspects such as financial services and industrial-financial docking, and officially completed the investment in 2023. In addition to "investment", Pudong Venture Capital pays more attention to "cultivation", and continues to build an industrial "circle of friends" for Kezhou Pharmaceuticals. For example, it participated in the first BioShanghai biopharmaceutical industrial-financial docking event linked to the city and recommended participation in the recording of the "Shanghai Practice·Science and Technology Innovation" series of feature films, helping the company to obtain more resources and more inspiration for development, and accelerate its progress towards the goal of becoming a chain leader in the biopharmaceutical field.
In May this year, the first prescription of the independently developed Tolametinib Capsules was issued, marking the official entry of the drug into the domestic market, bringing new treatment options to Chinese patients with advanced melanoma with NRAS mutations.
Recently, Haihe Pharmaceutical, a company invested by Pudong Venture Capital, also announced good news: the innovative MET inhibitor Glumetinib tablets with global independent intellectual property rights have been approved for marketing by the Ministry of Health, Labor and Welfare of Japan. The indication for this application is for the treatment of locally advanced or metastatic non-small cell lung cancer with MET14 exon skipping. Glumetinib is the first innovative drug approved for marketing in Japan by a Chinese biopharmaceutical company, and is another important achievement of China's innovative drugs going global.
Pudong Venture Capital completed its investment in Haihe Pharmaceutical in June 2023. Before the formal investment, Pudong Venture Capital set up a project working group to go deep into the company to understand its development history, current operation status and the difficulties encountered in the development process. Focusing on the development needs of enterprises, it maintains close linkage with enterprises in terms of policy consultation, capital empowerment, government-enterprise docking, post-investment services, etc., actively responds to the demands of industry enterprises, and continuously promotes the transformation of scientific research results.
"At present, we are still working with financial institutions to proactively meet the financing needs of invested companies, actively innovate financial products and services, and provide companies with more precise credit and financial support. We will work with a number of banks to jointly create a 'investment and loan linkage' credit product package exclusively for Pudong Venture Capital, helping scientific and technological innovation companies to run faster and more steadily." A relevant person in charge of Pudong Venture Capital said.
The launch of the "Chuang" enterprise post-investment service characteristic party building brand is also to further deeply integrate party building work with the main business of venture capital. Pudong Venture Capital will create a number of "Party member pioneer posts" and "pioneer party branches" to form a working situation of "everyone helps project investment and everyone empowers state-owned venture capital", focusing on leading projects in the industrial chain, and accelerating the layout of the entire industrial chain around GPU, humanoid robots, autonomous driving, synthetic biology, digital platforms, etc. So far, it has promoted the leading district fund to participate in the cultivation of more than 10 key projects of local super-large enterprises, completed 3 investments, involving an amount of about 2.7 billion yuan.
